Iran implemented the first human trial of Razi COV-pars, the second local vaccine it developed against the new variant of Coronavirus; the vaccine will be tested on 133 volunteers in the first phase.
COV-pars has been developed by Razi institute, which has been manufacturing serum and vaccine in Iran for 90 years, and the first human trial of this vaccine was applied in Tehran, attended by the Minister of Agriculture Kazem Khavazi.
Razi Institute Manager Ali Ishaki said that the first phase of the trial started today with 2 people and it will be administered to 133 volunteers; the second dose will be injected into the body 21 days later than the first dose, 51 days later for the dose administered through the nose.
Iran has tested its first local vaccine “COVIran Barekat” on humans for the first time on December 29, 2020 in a clinical trial phase and announced successful results.
Tayyibe Muhbir, the daughter of Mohammad Muhbir, who led the delegation of scientists, was the first volunteer to receive the vaccine.